Targeting Toll-like Receptors to Enhance Oncolytic Virotherapy: Strategies and Emerging Perspectives
- 1Department of Endocrinology, National Clinical Research Center for Children and Adolescents’ Health and Diseases, Children’s Hospital, Zhejiang University School of Medicine, Hangzhou 310052, China
- 2Department of Pediatrics, Affiliated Hospital of Zunyi Medical University, Zunyi 563000, China
Abstract
Oncolytic virotherapy (OVT) is a promising anticancer strategy, owing to its capacity to lyse tumor cells selectively and remodel the tumor microenvironment (TME) to enhance antitumor efficacy. Despite the continuous introduction and investigation of newly engineered oncolytic viruses (OVs) in clinical trials, their clinical translation remains limited, with Toll-like receptor (TLR)-mediated host immune responses representing a critical influencing factor. TLRs constitute a family of structurally conserved transmembrane proteins distributed on the plasma membrane and endosomal membranes. They initiate innate immune responses by recognizing pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs) and are essential for dendritic cells (DCs) maturation, playing a pivotal regulatory role across diverse tumor therapies. However, TLRs may also restrict viral replication and spread, and some studies suggest that they could, under certain conditions, act as drivers of tumor progression. Nonetheless, the role of TLRs in OVT has not been comprehensively summarized to date. In this review, we synthesize recent advances in the application of TLRs in OVT, with particular attention to their mechanisms of action and the challenges that remain to be overcome, and consider their prospects in oncology, offering insights that may inform the clinical translation of this therapeutic approach.
Related
- Unlocking oncolytic virotherapy potential: leveraging bacteriophages to conquer immunosuppression
- Liver-resident cellular determinants of oncolytic virotherapy in hepatocellular carcinoma: viral susceptibility and spatial immune remodeling.
- Oncolytic reovirus: tumor-microenvironment remodeling, engineering constraints, and translational strategies
- TOC159 receptors use a galactolipid-specific bipartite signal for chloroplast targeting in Arabidopsis thaliana
- Targeting Histamine H3 Receptors to Suppress NGF-Driven Hyperexcitability in Neuropathic Pain
BibTeX
@article{lan2026targeting,
title = {{Targeting Toll-like Receptors to Enhance Oncolytic Virotherapy: Strategies and Emerging Perspectives}},
author = {Siqian Lan and Xiaoqiang Hao and Dongming Zhou and Jinkai Peng and Zhengyan Zhao},
journal = {Biomolecules},
year = {2026},
month = oct,
doi = {10.3390/biom16111557},
url = {https://www.mdpi.com/2218-273X/16/11/1557},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Targeting Toll-like Receptors to Enhance Oncolytic Virotherapy: Strategies and Emerging Perspectives
AU - Siqian Lan
AU - Xiaoqiang Hao
AU - Dongming Zhou
AU - Jinkai Peng
AU - Zhengyan Zhao
PY - 2026
DA - 2026/10/26
JO - Biomolecules
DO - 10.3390/biom16111557
UR - https://www.mdpi.com/2218-273X/16/11/1557
AB - Oncolytic virotherapy (OVT) is a promising anticancer strategy, owing to its capacity to lyse tumor cells selectively and remodel the tumor microenvironment (TME) to enhance antitumor efficacy. Despite the continuous introduction and investigation of newly engineered oncolytic viruses (OVs) in clinical trials, their clinical translation remains limited, with Toll-like receptor (TLR)-mediated host immune responses representing a critical influencing factor. TLRs constitute a family of structurally conserved transmembrane proteins distributed on the plasma membrane and endosomal membranes. They initiate innate immune responses by recognizing pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs) and are essential for dendritic cells (DCs) maturation, playing a pivotal regulatory role across diverse tumor therapies. However, TLRs may also restrict viral replication and spread, and some studies suggest that they could, under certain conditions, act as drivers of tumor progression. Nonetheless, the role of TLRs in OVT has not been comprehensively summarized to date. In this review, we synthesize recent advances in the application of TLRs in OVT, with particular attention to their mechanisms of action and the challenges that remain to be overcome, and consider their prospects in oncology, offering insights that may inform the clinical translation of this therapeutic approach.
SN - 2218-273X
ER -